Aug
15
2025
RL-007 Poised to Transform CIAS Market as First Targeted Therapy for Cognitive Deficits in Schizophrenia | DelveInsight
As RL-007 progresses through late-stage clinical development, it represents a significant advancement in schizophrenia treatment, potentially offering one of the first approved therapies specifically …
